Cheaper keytruda copycat tested in lung cancer patients
NCT ID NCT07162883
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 3 trial tests QL2107, a biosimilar (copy) of the cancer drug Keytruda, in 122 adults with non-small cell lung cancer that has been surgically removed. The goal is to see if the body processes QL2107 the same way as Keytruda when given as an extra treatment after surgery and chemotherapy. If successful, it could lead to a lower-cost option for patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QL2107 (a biosimilar of pembrolizumab, the drug in Keytruda)
- What this could lead to
- If QL2107 works as well as Keytruda, it could offer a more affordable treatment option for lung cancer patients after surgery.
- What could go wrong
- This is an early-stage comparison study focused on drug levels, not yet on actual cancer outcomes. The biosimilar may not prove equally effective or safe in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immunotherapy be safely used in early lung cancer? a Real-World study investigates
- Can an oral chemo pill boost immunotherapy's power against lung cancer?
- Can an immunotherapy cocktail shrink inoperable lung tumors?
- Immunotherapy boosts radiation against early lung cancer
- Lab-Grown lung tumors could reveal why some drugs work and others fail
- AI-Powered navigation aims to pinpoint tiny lung nodules during surgery